Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.

Molecular cancer - 10 Feb 2022

Song Huibin, Liu Dongcheng, Wang Lingwei, Liu Kaisheng, Chen Chen, Wang Le, Ren Yi, Ju Bing, Zhong Fuhua, Jiang Xingyu, Wang Guangsuo, Chen Zhe-Sheng, Zou Chang

Abstract excerpt

BACKGROUND: Identification of potential novel targets for reversing resistance to Epidermal Growth Factor Receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) holds great promise for the treatment of relapsed lung adenocarcinoma (LUAD). In the present study, we aim to investigate the role of methyltransferase-like 7B (METTL7B) in inducing EGFR-TKIs resistance in LUAD and whether it could be a therapeutic target...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Chromatography, Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Methyltransferases

Share to Protein Kinase Inhibitors

Share to Tandem Mass Spectrometry

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 35144642
DOI: 10.1186/s12943-022-01519-7
PMCID: PMC8830004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.PMID 35144642Read ↗

METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells.Semantic proximity Read ↗

Association between methyltransferase-like 3 and non-small cell lung cancer: pathogenesis, therapeutic resistance, and clinical applicationsSemantic proximity Read ↗

METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modificationSemantic proximity Read ↗

NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancerSemantic proximity Read ↗

TIGAR promotes malignant proliferation of NSCLC by modulating deoxynucleotide anabolism via a YBX1-RRM2B axisSemantic proximity Read ↗

The role of m6A methylation in targeted therapy resistance in lung cancerSemantic proximity Read ↗

Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent mannerSemantic proximity Read ↗

Exosomal Delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent MannerSemantic proximity Read ↗

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Discovery of Highly Selective AKR1C3 Inhibitors to Overcome EGFR C797S-Mediated Osimertinib Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

TRMT1-Mediated tRNA m22G Modification Drives Osimertinib Resistance via the ATXN3/USP25 Axis in Lung AdenocarcinomaSemantic proximity Read ↗

Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.